Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 20/20 | 0.73 |
| ▸ | ATRIP | Q8WXE1 | 8/20 | 0.68 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.68 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.68 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.68 |
| ▸ | TAF1 | P21675 | 1/20 | 0.65 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.65 |
| ▸ | MTOR | P42345 | 1/20 | 0.65 |
| ▸ | PRKDC | P78527 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30629304 | 1.00 | ATR (0.73) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL7907534 | 0.87 | ATR (0.80) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL21263177 | 0.86 | ATR (0.75) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL21263052 | 0.86 | ATR (0.75) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL21263200 | 0.84 | ATR (1.00) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL21263192 | 0.84 | ATR (1.00) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL20798126 | 0.83 | ATR (0.78) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL30629308 | 0.83 | ATR (0.78) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL20798122 | 0.83 | ATR (0.78) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL15943625 | 0.83 | ATR (0.72) | ATRATRIPCHEK1PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111655688-B | Substituted pyrrolopyridines as ATR inhibitors | 蓝谷制药有限责任公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20220227755-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | GREENGENE BIOSCIENCES INC. | 2022-07-21 | — | — | US | disclosed |
| EP-3679041-B1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | NEWAVE PHARMACEUTICAL INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11236089-B2 | Substituted pyrrolopyridines as ATR inhibitors | BLUEVALLEY PHARMACEUTICAL LLC (US) | 2022-02-01 | — | — | US | disclosed |
| CN-111655688-A | Substituted pyrrolopyridines as ATR inhibitors | 蓝谷制药有限责任公司 | 2020-09-11 | — | — | CN | disclosed |
| EP-3679041-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | BLUEVALLEY PHARMACEUTICAL LLC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20200207763-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | GREENGENE BIOSCIENCES INC. | 2020-07-02 | — | — | US | disclosed |
| WO-2019050889-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | BLUEVALLEY PHARMACEUTICAL LLC (US) | 2019-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227755-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | ATR, RB1, ATRIP | ATR 1/4885ATRIP 3/4885CHEK1 5/4885 |
| US-11236089-B2 | Substituted pyrrolopyridines as ATR inhibitors | ATR, RB1, ATRIP | ATR 1/4885ATRIP 3/4885CHEK1 5/4885 |
| US-20200207763-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | ATR, RB1, ATRIP | ATR 1/4885ATRIP 3/4885CHEK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.